Look at Garren's statement. Afterthought or late addendum. The rationale appears logical.
According to the company they added the 10mg dose to this trial to get PK (pharmacokinetic) data. PK data is also being collected at the other 2 dose levels. Also they claim that the 10 mg dose can be reformulated in a manner that can be given without an IV infusion (subcutaneous injection, nasal spray, etc.). The concept would be more frequent but easier dosing—if it works. This could be a huge upside if the 10mg dose works.
Market Data 
Markets 
AI
